^
Association details:
| Biomarker: | AR overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC.
Excerpt:
Among patients with high % of AR+ tumor cells, 11 received enzalutamide, with 43% (3/7) having responses (pCR or RCB-I)….We observed a trend where response rate was higher in patients with ≥ AR+ IHC scores treated with enzalutamide…
DOI:
10.1200/JCO.2019.37.15_suppl.595
